Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2015

Open Access 01-12-2015 | Research article

Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease

Authors: Gülmisal Güder, Susanne Brenner, Stefan Störk, Matthias Held, Berna DL Broekhuizen, Jan-Willem J Lammers, Arno W Hoes, Frans H Rutten

Published in: BMC Pulmonary Medicine | Issue 1/2015

Login to get access

Abstract

Background

The maximal expiratory flow at 50 % of the forced vital capacity (MEF50) is the flow where half of forced vital capacity (FVC) remains to be exhaled. A reduced MEF50 has been suggested as a surrogate marker of small airways disease. The diagnostic and prognostic utility of this easy to assess spirometric variable in persons with respiratory symptoms, but without COPD is unclear.

Methods

We used data from the UHFO-COPD cohort in which 405 community-dwelling persons aged 65 years or over, and a general practitioner’s diagnosis of chronic obstructive pulmonary disease (COPD) underwent pulmonary function testing and echocardiography. In total 161 patients had no COPD according to the spirometric GOLD criteria. We considered MEF50 as reduced if < 60 % of predicted.

Results

Of the 161 patients without COPD (mean age 72 ± 5.7 years; 35 % male; follow-up 4.5 ± 1.1 years), 61 (37.9 %) had a reduced MEF50. They were older, had more pack-years of smoking, more respiratory symptoms, and used more frequently inhaled medication than the remaining 100 subjects. A reduced MEF50 was nearly twice as often associated with newly detected heart failure (HF) at assessment (29.5 % vs. 15.6 %, p = 0.045). In age-and sex-adjusted Cox regression analysis, a reduced MEF50 was significantly associated with episodes of acute bronchitis (hazard ratio 2.54 95 % confidence interval (1.26; 5.13) P = 0.009), and in trend with pneumonia (2.14 (0.98; 4.69) P = 0.06) and hospitalizations for pulmonary reasons (2.28 (0.93; 5.62) P = 0.07).

Conclusions

In older community-dwelling persons with pulmonary symptoms but without COPD, a reduced MEF50 may help to uncover unrecognized HF, and identify those at a higher risk for episodes of acute bronchitis, pneumonia and hospitalizations for pulmonary reasons. Echocardiography and close follow-up should be considered in these patients.
Literature
1.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed
2.
go back to reference Bar-Yishay E, Amirav I, Goldberg S. Comparison of maximal midexpiratory flow rate and forced expiratory flow at 50 x% of vital capacity in children. Chest. 2003;123:731–5. Bar-Yishay E, Amirav I, Goldberg S. Comparison of maximal midexpiratory flow rate and forced expiratory flow at 50 x% of vital capacity in children. Chest. 2003;123:731–5.
3.
go back to reference McFadden Jr ER, Linden DA. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med. 1972;52:725–37.CrossRefPubMed McFadden Jr ER, Linden DA. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med. 1972;52:725–37.CrossRefPubMed
4.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68.CrossRefPubMed Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68.CrossRefPubMed
5.
go back to reference Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.CrossRefPubMedPubMedCentral Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.CrossRefPubMedPubMedCentral
6.
go back to reference Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev. 2011;20:23–33.CrossRefPubMed Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev. 2011;20:23–33.CrossRefPubMed
7.
go back to reference Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985). 2008;104:394–403.CrossRef Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985). 2008;104:394–403.CrossRef
8.
go back to reference Burgel PR, Bergeron A, De Blic J, Bonniaud P, Bourdin A, Chanez P, et al. Small airways diseases, excluding asthma and COPD: an overview. Eur Respir Rev. 2013;22:131–47.CrossRefPubMed Burgel PR, Bergeron A, De Blic J, Bonniaud P, Bourdin A, Chanez P, et al. Small airways diseases, excluding asthma and COPD: an overview. Eur Respir Rev. 2013;22:131–47.CrossRefPubMed
9.
go back to reference Zanen P, Folgering H, Lammers JW. Flow-volumes indices as means to discriminate between intra-and extrapulmonary restrictive disease. Respir Med. 2005;99:825–9.CrossRefPubMed Zanen P, Folgering H, Lammers JW. Flow-volumes indices as means to discriminate between intra-and extrapulmonary restrictive disease. Respir Med. 2005;99:825–9.CrossRefPubMed
10.
go back to reference Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–94.CrossRefPubMed Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–94.CrossRefPubMed
11.
go back to reference Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed
12.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.CrossRefPubMed Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.CrossRefPubMed
13.
go back to reference Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–67.CrossRefPubMed Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–67.CrossRefPubMed
14.
go back to reference Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284–9.CrossRefPubMed Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284–9.CrossRefPubMed
15.
go back to reference Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865–75.CrossRefPubMed Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865–75.CrossRefPubMed
16.
go back to reference Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182–8.CrossRefPubMed Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182–8.CrossRefPubMed
17.
go back to reference Shaw RJ, Djukanovic R, Tashkin DP, Millar AB, Du Bois RM, Orr PA. The role of small airways in lung disease. Respir Med. 2002;96:67–80.CrossRefPubMed Shaw RJ, Djukanovic R, Tashkin DP, Millar AB, Du Bois RM, Orr PA. The role of small airways in lung disease. Respir Med. 2002;96:67–80.CrossRefPubMed
18.
go back to reference Mirsadraee M, Boskabady MH, Attaran D. Diagnosis of chronic obstructive pulmonary disease earlier than current Global Initiative for Obstructive Lung Disease guidelines using a feasible spirometry parameter (maximal-mid expiratory flow/forced vital capacity). Chron Respir Dis. 2013;10:191–6.CrossRefPubMed Mirsadraee M, Boskabady MH, Attaran D. Diagnosis of chronic obstructive pulmonary disease earlier than current Global Initiative for Obstructive Lung Disease guidelines using a feasible spirometry parameter (maximal-mid expiratory flow/forced vital capacity). Chron Respir Dis. 2013;10:191–6.CrossRefPubMed
19.
go back to reference Hansell DM. Small airways diseases: detection and insights with computed tomography. Eur Respir J. 2001;17:1294–313.CrossRefPubMed Hansell DM. Small airways diseases: detection and insights with computed tomography. Eur Respir J. 2001;17:1294–313.CrossRefPubMed
20.
go back to reference Guder G, Brenner S, Stork S, Hoes A, Rutten FH. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail. 2014;16:1273–82.CrossRefPubMed Guder G, Brenner S, Stork S, Hoes A, Rutten FH. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail. 2014;16:1273–82.CrossRefPubMed
21.
go back to reference Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart failure–COPD or congestion? Int J Cardiol. 2013;168:1910–6.CrossRefPubMed Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart failure–COPD or congestion? Int J Cardiol. 2013;168:1910–6.CrossRefPubMed
22.
go back to reference Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999;99:1190–6.CrossRefPubMed Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999;99:1190–6.CrossRefPubMed
23.
go back to reference Guder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep. 2014;11:337–46.CrossRefPubMed Guder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep. 2014;11:337–46.CrossRefPubMed
24.
go back to reference Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18:637–44.CrossRefPubMed Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18:637–44.CrossRefPubMed
25.
go back to reference Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.CrossRefPubMedPubMedCentral Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.CrossRefPubMedPubMedCentral
26.
go back to reference Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population-The CARLA Study. PLoS One. 2013;8, e59225.CrossRefPubMedPubMedCentral Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population-The CARLA Study. PLoS One. 2013;8, e59225.CrossRefPubMedPubMedCentral
27.
go back to reference Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–27.CrossRefPubMed Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–27.CrossRefPubMed
28.
go back to reference Held M, Mittnacht M, Karl S, Kolb M, Jany B. Pulmonary and Cardiac Function in asymptomatic Obese Subjects and Changes following a Structured weight reduction Program: a Prospective Observational Study. PLoS One. 2014;9(9):e107480.CrossRefPubMedPubMedCentral Held M, Mittnacht M, Karl S, Kolb M, Jany B. Pulmonary and Cardiac Function in asymptomatic Obese Subjects and Changes following a Structured weight reduction Program: a Prospective Observational Study. PLoS One. 2014;9(9):e107480.CrossRefPubMedPubMedCentral
29.
go back to reference Lazarus R, Sparrow D, Weiss ST. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest. 1997;111:891–8.CrossRefPubMed Lazarus R, Sparrow D, Weiss ST. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest. 1997;111:891–8.CrossRefPubMed
Metadata
Title
Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease
Authors
Gülmisal Güder
Susanne Brenner
Stefan Störk
Matthias Held
Berna DL Broekhuizen
Jan-Willem J Lammers
Arno W Hoes
Frans H Rutten
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2015
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-015-0081-4

Other articles of this Issue 1/2015

BMC Pulmonary Medicine 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.